TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned computed tomography urogram (CTU)~* Statin naive, or not on statin treatment for at least 14 day~Exclusion Criteria:~* History of liver disease or elevated serum transaminases~* History of rhabdomyolysis or elevated creatinine kinase~* History of iodinated CM use within 14 days before randomization~* History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.~* History of hypersensitivity reaction to contrast media~* Pregnancy or lactation~* Acute renal failure~* End-stage renal disease requiring dialysis~* Cardiogenic shock or pulmonary edema~* Multiple myeloma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin-Ascorbic acid (Type: ACTIVE_COMPARATOR): atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postpartum women who are interested in pharmacologic lactation suppression~2. Women over the age of 18~Exclusion Criteria:~1. Women with known sensitivity to vitamin B6 or Cabergoline~2. Women with hypertensive Disorders or contraindication to Cabergoline.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Administration of Cabergoline (Type: ACTIVE_COMPARATOR): one dose of 1mg, up to 24 hours postpartum, or 0.25 mg twice a day for two days
- Administration of Vitamin B6 (Type: ACTIVE_COMPARATOR): 200 mg X 3 per day for a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 1L- vs. 4L-PEG for Bowel Preparation Among Inpatients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult inpatients scheduled for colonoscopy for any indication within the normal process of care.~Exclusion Criteria:~* patients who underwent emergency or elective therapeutic colonoscopies (e.g. polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection)~* patients who underwent bowel preparation outside the hospital

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1L-PEG (Type: None): Hospitalized patients who are prescribed colonoscopy with 1L-polyethylene glycole (PEG) plus ascorbic acid as bowel preparation.
- 4L-PEG (Type: None): Hospitalized patients who are prescribed colonoscopy with 4L-polyethylene glycole (PEG) as bowel preparation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 2 to 59 months who present to LHWs with severe pneumonia.~* Informed consent given by a legal guardian.~Exclusion Criteria:~* Very severe disease.~* Persistent vomiting.~* Parental or caretaker refusal to participate in the study.~* Children currently being treated for non-severe pneumonia who advance to severe pneumonia.~* Suspected or known kerosene oil ingestion.~* Prior enrollment in the study within 2 weeks of last follow up~* Children with severe malnutrition . Children with severe diarrhea with signs of dehydration

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: OTHER): Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
- Control (Type: OTHER): LHWs refer the severe pneumonia case to local health facility or private practitioner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 to 80 years with Type 2 Diabetes who are on a stable dose of antidiabetic medication for at least 3 months~Exclusion Criteria:~* Patients taking Cholestin, niacin (\>50 mg/day), fibrate therapy, hormonal contraceptives, intermittent Hormone Replacement Therapy, or certain corticosteroids~* Patients with any of the following conditions: active liver disease or kidney disease, poorly controlled high blood pressure, active peptic ulcer, or other heart or blood diseases~* Patients with abnormal laboratory results from a blood test that will be given before starting the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sensitive Periods in Human Flavor Learning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, term infants and their mothers~* Infants 2 wks (+/- 2 wk of age)~* Mothers and infants exclusively breastfeeding or exclusively feeding a cows-milk based formula~* Mothers must be older than 18 years of age~Exclusion Criteria:~* Infants who were preterm or have medical conditions that interfere with feeding or eating~* Mothers who had gestational diabetes or are diagnosed with a major illness requiring treatment or surgery~* Mothers who will be going back to work full-time before the infant is 4 months old~* Mothers who are allergic to any vegetables~* Subjects will not be excluded because of economic status, gender, race or ethnicity.

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 3 Weeks
- Healthy Volunteers: t

Study Arms:
- 1M0.5 (Type: EXPERIMENTAL): Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience
- 1M1.5 (Type: EXPERIMENTAL): Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience
- 3M0.5 (Type: EXPERIMENTAL): Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience
- Control (Type: NO_INTERVENTION): Mothers will not receive the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months.~* MMSE score of 20 to 28 (inclusive) at baseline or an acceptable historical flortaucipir PET scan within 6 months prior to baseline that meets the central read criteria.~* Meet 18F flortaucipir PET scan eligibility criteria.~* Meet 18F florbetapir PET scan (central read) eligibility criteria.~Exclusion Criteria:~* Have a history of long QT syndrome.~* Have received treatment with a stable dose of an acetylcholinesterase inhibitor (AChEI) and/or memantine for less than 2 months before randomization.~* Contraindication to MRI.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Donanemab Monotherapy (Donanemab-M) (Type: EXPERIMENTAL): Participants received 700 milligram (mg) donanemab intravenously (IV) every 4 weeks (Q4W) x 3 doses, then 1400 mg donanemab IV Q4W for up to 72 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo IV Q4W for up to 72 weeks.
- Donanemab in Combination With LY3202626 (Donanemab-C) (Type: EXPERIMENTAL): Participants received 700 mg donanemab IV Q4W x 3 doses, then 1400 mg donanemab IV Q4W in combination with 12 mg of LY3202626 orally for up to 72 weeks.~As per protocol amendment (d) approved on Oct 9, 2018, donanemab in combination with LY3202626 (donanemab-C) arm discontinued as there was a low probability of identifying a statistically significant effect of 12mg of LY3202626 slowing cognitive decline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males in good general health and at least 50 years of age, with symptoms of moderate to severe BPH.~Exclusion Criteria:~* Medical conditions that would confound the efficacy evaluation.~* Medical conditions in which it would be unsafe to use an alpha-blocker.~* The use of concomitant drugs that would confound the efficacy evaluation.~* The use of concomitant drugs that would be unsafe with this alpha-blocker.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: EXPERIMENTAL): Silodosin 8 mg/Day with food
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsule once daily with food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected prostate cancer~* Planned prostate biopsy~* Able to provide written consent~* Karnofsky performance status of 50 (or ECOG/WHO equivalent)~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam~* Metallic implants (contraindicated for MRI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68Ga RM2 first followed by 68Ga PSMA11 (Type: EXPERIMENTAL): Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
- 68Ga PSMA11 first followed by 68Ga RM2 (Type: EXPERIMENTAL): Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female and male patients aged ≥18 and ≤ 90 years~* Two consecutive i-STAT potassium values, measured 60-minutes (± 10 minutes) apart, both ≥ 5.1 mmol/l and measured within 1 day of the first ZS dose on 48-hour open-label initial phase Day 1~* Ability to have repeated blood draws or effective venous catheterization~* Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy.~Exclusion Criteria:~* Involvement in the planning and/or conduct of the study~* Participation in another clinical study with an investigational product during the last 3 months~* Pseudohyperkalemia signs and symptoms~* Patients treated with lactulose, xifaxan (rifaximin) or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug~* Patients treated with resins,calcium acetate,calcium carbonate, or lanthanum carbonate,within 7 days prior to the first dose of study drug~* Patients with a life expectancy of less than 3 months~* Patients who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol~* Female patients who are pregnant, lactating, or planning to become pregnant~* Patients with diabetic ketoacidosis~* Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof~* Patients with cardiac arrhythmias that require immediate treatment~* Patients on dialysis~* Patients who are blood donors should not donate blood during the study and for 3 months following their last dose of ZS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Zirconium Cyclosilicate (ZS) 5g (Type: EXPERIMENTAL): Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
- Sodium Zirconium Cyclosilicate (ZS) 10g (Type: EXPERIMENTAL): Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
- Placebo (Type: PLACEBO_COMPARATOR): Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients Have Type 2 Diabetes Mellitus On Diet/Exercise Therapy~Exclusion Criteria:~* Patients Have Type 1 Diabetes Mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): Sitagliptin 100 mg
- 3 (Type: EXPERIMENTAL): Sitagliptin 50 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vitamin D After Application With Valchlor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be in general good health~* Fitzpatrick Skin Type I-VI~* Able to list all current medications and medical conditions~* Capable of giving informed consent~Exclusion Criteria:~* Women who are pregnant, nursing, or who may become pregnant in the next 3 months~* Participants taking illegal drugs~* Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil~* Currently consuming 800IU or more of vitamin D a day~* Subjects whose BMI are \> 40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: 4 placebo - 0 Vitamin D with Valchlor (Type: PLACEBO_COMPARATOR): Participants will be given 4 placebo capsules and 0 cholecalciferol (Vitamin D) capsules after being treated with Valchlor.
- Group 2: 0 placebo - 4 Vitamin D with mechloroethamine (Type: EXPERIMENTAL): Participants will be given 0 placebo capsules and 4 cholecalciferol capsules to total 200,000 IU of cholecalciferol (Vitamin D) after being treated with Valchlor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inpatient Diabetes on Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior history of diabetes~* Able to provide informed consent~* Receiving corticosteroids while hospitalized of greater than 10 mg/d prednisone or the equivalent of dexamethasone or methylprednisolone~* Expect to be hospitalized for 48 hours~Exclusion Criteria:~* Renal failure with GFR (glomerular filtration rate) \< 30 ml/min/1.73m2~* ALT (alanine aminotransferase) \> 2 times upper normal for laboratory

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- NPH with steroid dose (Type: EXPERIMENTAL): Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg
- Control - Background and correction insulin (Type: ACTIVE_COMPARATOR): Receive usual care with background insulin and correction factor for duration of study (2-5 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or more.~2. Gestational age of pregnancy of 37 completed weeks or more.~3. Written and signed informed consent by the patient to participate in the study.~Exclusion Criteria:~1. fetal or maternal distress where, due to time constraints, it will not possible and/or appropriate to recruit or randomize.~2. Women undergoing caesarean section with general anesthesia are also excluded, because carbetocin is licensed for use with regional anaesthesia only.~3. Women planned to have any other type of uterine incision other than transverse lower segment.~4. Women with HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), eclampsia, and epilepsy .~5. Women with placental abruption are excluded because there is a higher risk of hemorrhage with this condition and it was therefore felt to be inappropriate to recruit these women.~6. Women with thrombocytopenia, known coagulopathies, or receiving anticoagulant therapy.~7. Women with history of significant heart disease, a history or evidence of liver, renal, vascular disease or endocrine disease (other than gestational diabetes).~8. Women with history of hypersensitivity to oxytocin or carbetocin.~9. Women with any severe allergic condition or severe asthma.~10. Women with any contraindication to receiving prostaglandins, including known hypersensitivity to misoprostol or other prostaglandins (PGs) or glaucoma.~11. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Syntocinon (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.
- Carbetocin (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.
- Misoprostol (Type: ACTIVE_COMPARATOR): Drug is given just after delivery of the neonate during cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete